

## Faculty Disclosures

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, course directors, planners, moderators, faculty, and all others in control of the educational content of the continuing education activity must disclose all financial relationships with ineligible companies that they may have had within the past 24 months. If an individual refuses to disclose financial relationships, they will be disqualified from being a part of the planning and implementation of the activity. Owners and/or employees of an ineligible company with business lines or products relating to the content of the activity will not be permitted to participate in the planning or execution of any accredited program. All listed relevant financial relationships with ineligible companies for individuals in control of content have been mitigated.

Name	Role in Activity	Ineligible Company	Nature of Relevant Financial Relationship
Charlton	Speaker	<ul style="list-style-type: none"> <li>Intercept Pharmaceuticals, Inc., Siemens Medical Solutions USA, Inc.</li> </ul>	<ul style="list-style-type: none"> <li>Speakers Bureau</li> </ul>
		<ul style="list-style-type: none"> <li>E.R. Squibb &amp; Sons, L.L.C., Gilead Sciences, Inc., Novo Nordisk</li> </ul>	<ul style="list-style-type: none"> <li>Consultant</li> <li>Advisor</li> </ul>
		<ul style="list-style-type: none"> <li>Terns Pharmaceuticals, Inc</li> </ul>	<ul style="list-style-type: none"> <li>Advisor</li> </ul>
Deising	Speaker	<ul style="list-style-type: none"> <li>None</li> </ul>	<ul style="list-style-type: none"> <li>N/A</li> </ul>
Frenette	Speaker	<ul style="list-style-type: none"> <li>Bayer, Bristol Myers Squibb, Eisai, Exelixis, Genentech, Gilead Sciences, Inc, Intercept Pharmaceuticals, Salix Pharmaceutical</li> </ul>	<ul style="list-style-type: none"> <li>Speakers Bureau</li> </ul>
		<ul style="list-style-type: none"> <li>AstraZeneca, Bayer, Exelixis, Eisai, Genentech, Gilead Sciences, Inc, Merck</li> </ul>	<ul style="list-style-type: none"> <li>Advisory Board</li> </ul>
		<ul style="list-style-type: none"> <li>Bayer Pharmaceuticals, Merck</li> </ul>	<ul style="list-style-type: none"> <li>Research Support</li> </ul>
		<ul style="list-style-type: none"> <li>Bayer Pharmaceuticals, Eisai, Genentech, Merck</li> </ul>	<ul style="list-style-type: none"> <li>Consultant</li> </ul>
Gutierrez	Speaker	<ul style="list-style-type: none"> <li>Durect Corporation</li> </ul>	<ul style="list-style-type: none"> <li>Research funding</li> </ul>
		<ul style="list-style-type: none"> <li>AbbVie, Alexion, Gilead Sciences, Inc, Exelixis, Intercept Pharmaceuticals</li> </ul>	<ul style="list-style-type: none"> <li>Speaker, Advisory Board</li> </ul>
		<ul style="list-style-type: none"> <li>ProSciento</li> </ul>	<ul style="list-style-type: none"> <li>Researcher</li> </ul>
		<ul style="list-style-type: none"> <li>Merck, Metacrine, Regeneron</li> </ul>	<ul style="list-style-type: none"> <li>Principle Investigator</li> </ul>
Kowdley	Speaker	<ul style="list-style-type: none"> <li>CymaBay Therapeutics, Genfit, HighTide, Mirum Pharmaceuticals, Madrigal Pharmaceuticals, NGM Pharmaceuticals</li> </ul>	<ul style="list-style-type: none"> <li>Research Support, Consultant</li> </ul>
		<ul style="list-style-type: none"> <li>Gilead Sciences, Inc., Intercept Pharmaceuticals</li> </ul>	<ul style="list-style-type: none"> <li>Research Support, Consulting, Speaker</li> </ul>
		<ul style="list-style-type: none"> <li>Hanmi Pharm Co., Ltd, Pliant Therapeutics, Metacrine, Pfizer Inc, Viking Therapeutics</li> </ul>	<ul style="list-style-type: none"> <li>Research Support</li> </ul>
Lane	Peer Reviewer	<ul style="list-style-type: none"> <li>None</li> </ul>	<ul style="list-style-type: none"> <li>N/A</li> </ul>
Morgan	Speaker	<ul style="list-style-type: none"> <li>AbbVie Gilead Sciences, Inc, Genfit, Merck</li> </ul>	<ul style="list-style-type: none"> <li>Research Funding</li> </ul>
Noureddin	Speaker	<ul style="list-style-type: none"> <li>89BIO, Altimune, Blade Therapeutics, Inc, EchoSens, Fractyl, Gilead Sciences, Inc, cohBar, Cytodyn, Intercept Pharmaceuticals,</li> </ul>	<ul style="list-style-type: none"> <li>Advisory board</li> </ul>

		Pfizer, Novo Nordisk, Madrigal, Terna, Roche diagnostic, Siemens	
		<ul style="list-style-type: none"> <li>Allergan, Bristol Myers Squibb, Gilead Sciences, Inc, Galmed, Galectin, Genfit, Conatus, Enanta, Madrigal, Novartis, Pfizer, Shire, Viking Therapeutics, Inc. Zydus</li> </ul>	<ul style="list-style-type: none"> <li>Research Grants</li> </ul>
		<ul style="list-style-type: none"> <li>Anaetos, Rivus Pharma and Viking Therapeutics, Inc</li> </ul>	<ul style="list-style-type: none"> <li>Shareholder</li> </ul>
<b>Northup</b>	Speaker	<ul style="list-style-type: none"> <li>None</li> </ul>	<ul style="list-style-type: none"> <li>N/A</li> </ul>
<b>Pockros</b>	Course Director, Moderator, Speaker	<ul style="list-style-type: none"> <li>AbbVie, Intercept Pharmaceuticals</li> </ul>	<ul style="list-style-type: none"> <li>Speakers Bureau, Advisory Boards</li> </ul>
		<ul style="list-style-type: none"> <li>AbbVie, Bayer, Gilead Sciences, Inc, Intercept Pharmaceuticals</li> </ul>	<ul style="list-style-type: none"> <li>Unrestricted CME funds to University of Louisville/ SC Liver Research Consortium</li> </ul>
<b>Skinner</b>	Speaker	<ul style="list-style-type: none"> <li>None</li> </ul>	<ul style="list-style-type: none"> <li>N/A</li> </ul>
<b>Terrault</b>	Speaker	<ul style="list-style-type: none"> <li>Genentech-Roche Gilead Sciences, Inc</li> </ul>	<ul style="list-style-type: none"> <li>Grants, Contracts, Research</li> </ul>
		<ul style="list-style-type: none"> <li>Exigo Mgmt LLC, ENYO, PPD Pharma, Entourage</li> </ul>	<ul style="list-style-type: none"> <li>Consultant</li> </ul>
		<ul style="list-style-type: none"> <li>Helio Health, Durect Corporation</li> </ul>	<ul style="list-style-type: none"> <li>Grant</li> </ul>
<b>Vierling</b>	Speaker	<ul style="list-style-type: none"> <li>None</li> </ul>	<ul style="list-style-type: none"> <li>N/A</li> </ul>
<b>Wong</b>	Speaker	<ul style="list-style-type: none"> <li>Mallinckrodt Pharmaceutical, Sequana medical</li> </ul>	<ul style="list-style-type: none"> <li>Research grant paid to institution</li> </ul>
		<ul style="list-style-type: none"> <li>Ocelot Bio, River 2 Renal Corporation</li> </ul>	<ul style="list-style-type: none"> <li>Consultant</li> </ul>
<b>CME Committee</b>	CE approval, all final decision-making on activities	<ul style="list-style-type: none"> <li>None</li> </ul>	<ul style="list-style-type: none"> <li>N/A</li> </ul>
<b>Scripps Conference Services &amp; CME</b>	Plan, manage, implement, and reconcile CE activities	<ul style="list-style-type: none"> <li>None</li> </ul>	<ul style="list-style-type: none"> <li>N/A</li> </ul>

### Glossary of Terms

#### Ineligible Company

An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. For specific examples of ineligible companies visit [www.accme.org/standards](http://www.accme.org/standards).

#### Financial Relationships

Financial relationships include employee, researcher, consultant, advisor, speaker, independent contractor, research funding, royalties or patent beneficiary, executive role, and ownership interest. Individual stocks and stock options should be disclosed.